Buy Rating Affirmed on PDS Biotechnology’s Promising HNSCC Treatment Developments

PDS Biotechnology (PDSB – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on the stock and has a $21.00 price target.

Joseph Pantginis has given his Buy rating due to a combination of factors surrounding PDS Biotechnology’s promising developments in their clinical trials. The VERSATILE-002 study outcomes have been particularly impressive, showcasing the potential of PDS0101 in combination with pembrolizumab (Keytruda) to address an unmet need in the treatment of recurrent and metastatic HPV-positive head and neck squamous cell carcinoma (HNSCC). Pantginis’s optimism is further bolstered by the company’s plans to launch a pivotal Phase 3 trial by the end of 2024, which includes an innovative triple combination arm that could significantly improve treatment outcomes for patients.

Additionally, the updated data from the VERSATILE-002 trial indicates that PDS0101 has a differentiated clinical benefit, especially in CKI naïve patients, with encouraging overall response rates and median progression-free survival metrics. These findings suggest that PDS0101, in conjunction with Keytruda, may offer superior survival benefits compared to existing immunotherapy options. Pantginis’s conviction in assigning a Buy rating is rooted in these clinical results and the strategic direction PDS Biotechnology is taking toward addressing the significant unmet clinical needs within the HNSCC patient population.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

PDS Biotechnology (PDSB) Company Description:

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded on March 15, 2019 and is headquartered in Berkeley Heights, NJ.